140 related articles for article (PubMed ID: 28050230)
1. Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
Li Y; Zhao K; Yao C; Kahwash S; Tang Y; Zhang G; Patterson K; Wang QE; Zhao W
Genes Cancer; 2016 Sep; 7(9-10):292-300. PubMed ID: 28050230
[TBL] [Abstract][Full Text] [Related]
2. Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines.
Yao C; Zhang G; Walker A; Zhao KY; Li Y; Lyu L; Tang Y; Ru P; Jones D; Zhao W
Leuk Res; 2017 Sep; 60():129-134. PubMed ID: 28818808
[TBL] [Abstract][Full Text] [Related]
3. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
7. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG
Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
Liu YY; You LS; Qian WB; Tong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):473-8. PubMed ID: 23086637
[TBL] [Abstract][Full Text] [Related]
9. [Anti-leukemia effect of oridonin on Ph(+) acute lymphoblastic leukemia cell SUP-B15].
Guo Y; Shan QQ; Gong YP; Lin J; Yang X; Zhou RQ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):439-43. PubMed ID: 22967375
[TBL] [Abstract][Full Text] [Related]
10. [Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms].
Deng Y; Tao SD; Zhang X; Ma JJ; He ZM; Chen Y; Deng ZK; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):72-79. PubMed ID: 28245378
[TBL] [Abstract][Full Text] [Related]
11. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
13. miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.
Jiang T; Chen J; Huang XB; Li YX; Zhong L
Neoplasma; 2018 Nov; 65(6):907-914. PubMed ID: 30334451
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
16. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
17. Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells.
Zhang C; Zhang X; Yang SJ; Chen XH
Oncol Lett; 2017 Apr; 13(4):2059-2070. PubMed ID: 28454362
[TBL] [Abstract][Full Text] [Related]
18. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
Xing H; Yang X; Liu T; Lin J; Chen X; Gong Y
Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
[TBL] [Abstract][Full Text] [Related]
19. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
20. Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Naren D; Wu J; Gong Y; Yan T; Wang K; Xu W; Yang X; Shi F; Shi R
Leuk Res; 2016 Mar; 42():59-67. PubMed ID: 26818574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
